News & Media
BIOGENERA SpA has officially signed an agreement with CVBF (Consortium for Biological and Pharmacological Evaluations) to monitor and execute the phase I clinical trial of the new drug BGA002, intended for the treatment of aggressive pediatric cancers associated with alterations in the MYCN tumor gene.
- Corporate Update
Funding from the European Community (Horizon program) has been approved for the biomedical research program called ARACHNID (Automated canceR-on-A-CHip orgaN-specific metastatIc spreaD), which will be carried out in collaboration between BIOGENERA’s R&D team and the research group of Prof. Elisa Cimetta of the University of Padua.
- Corporate Update
The Paris Saclay Cancer Cluster is located in Paris, in the Villejuif area, and is the first oncology cluster in France, recognized as an international excellence. The PSCC promotes collaboration among scientific, medical and industrial communities internationally, providing access to cutting-edge resources and treatments.
- Corporate Update
Il team di Biogenera ha raggiunto un risultato fondamentale nello sviluppo dell’ innovativo farmaco anti-tumorale BGA002: un farmaco rivoluzionario che si concentra su tumori aggressivi sia nei bambini che negli adulti, colpendo specificamente le cellule tumorali e risparmiando quelle sane.
- Corporate Update